Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||AZD9150 + Carboplatin + Durvalumab + Nab-paclitaxel|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AZD9150||ISIS 481464|ISIS-STAT3rx|Danvatirsen||STAT3 Inhibitor 25||ISIS-STAT3rx (AZD9150) is an antisense oligonucleotide that inhibits translation of STAT3, which is often activated by receptor tyrosine kinases including FGFR, thereby preventing cell proliferation (PMID: 23935373, PMID: 30661177).|
|Carboplatin||Paraplatin||CBDCA||Chemotherapy - Platinum 7||Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary).|
|Durvalumab||Imfinzi||MEDI4736||Immune Checkpoint Inhibitor 146 PD-L1/PD-1 antibody 107||Imfinzi (durvalumab) is a monoclonal antibody that binds to and inhibits PD-L1 (CD274), potentially resulting in increased immune response to tumors (PMID: 25943534, PMID: 28214651). Imfinzi (durvalumab) is FDA approved for use in patients with urothelial carcinoma and unresectable, stage III non-small cell lung cancer, in combination with Imjudo (tremelimumab) and platinum-based chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, in combination with etoposide and carboplatin or cisplatin in patients with extensive stage small cell lung cancer, in combination with cisplatin and gemcitabine in patients with locally advanced or metastatic biliary tract cancer, and in combination with Imjudo (tremelimumab) in adult patients with unresectable hepatocellular carcinoma (FDA.gov).|
|Nab-paclitaxel||Abraxane||ABI-007|Paclitaxel Protein-bound||Chemotherapy - Taxane 2||Abraxane (nab-paclitaxel) is an albumin-stablized version of paclitaxel, which binds microtubules and prevents depolymerization, resulting in decreased cell motility and division (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03421353||Phase Ib/II||AZD9150 + Cisplatin + Durvalumab + Gemcitabine AZD9150 + Carboplatin + Durvalumab + Gemcitabine AZD9150 + Cisplatin + Durvalumab + Fluorouracil AZD9150 + Durvalumab AZD9150 + Carboplatin + Durvalumab + Nab-paclitaxel||AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer||Active, not recruiting||USA||0|